MedTrace Logo

A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease

NCT00165672 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2011-10-05

Study results available
· View outcomes & findings →

Summary

To investigate esophageal reflux condition in patients with non-erosive gastroesophageal reflux disease by assessing with a 24-hour esophageal pH monitoring or effects of a 4-week treatment with 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)).

Conditions

  • Non-erosive Gastroesophageal Reflux Disease

Interventions

DRUG

RABEPRAZOLE SODIUM

rabeprazole sodium 5 mg: once daily orally for 4 weeks

DRUG

RABEPRAZOLE SODIUM

rabeprazole sodium 10 mg: once daily orally for 4 weeks

Sponsors & Collaborators

  • Eisai Limited

    collaborator INDUSTRY

  • Eisai Inc.

    lead INDUSTRY

Principal Investigators

  • Nobuyuki Sugisaki · Eisai Co., Ltd - Development Clinical Research Department. Clinical Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2005-10-31
Completion
2005-10-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00165672 on ClinicalTrials.gov